

## **New perspectives on the adverse effects of NSAIDs in cancer pain: An Italian Delphi study from the Rational Use of Analgesics (RUA) group**

**Authors:** Giustino Varrassi<sup>1</sup>, Flaminia Coluzzi<sup>2,3</sup>, Diego Fornasari<sup>4</sup>, Flavio Fusco<sup>5</sup>, Walter Gianni<sup>6</sup>, Andrea Vittorio Guardamagna<sup>7</sup>, Filomena Puntillo<sup>8</sup>, Giovanni Sotgiu<sup>9</sup>

### **Affiliations:**

<sup>1</sup> Paolo Procacci Foundation, Rome, Italy

<sup>2</sup> Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, Italy

<sup>3</sup> Anesthesiology, Intensive Care, and Pain Medicine Unit, Sant'Andrea University Hospital, Rome, Italy

<sup>4</sup> Department of Medical Biotechnology and Molecular Medicine, Università degli Studi di Milano, Milan, Italy

<sup>5</sup> Palliative Care Unit, Department of Primary and Community Care, ASL3 Liguria, Italy

<sup>6</sup> RCCS Santa Lucia Foundation, Rome, Italy

<sup>7</sup> Pain Medicine Unit, Istituto Europeo Oncologico, Milan, Italy

<sup>8</sup> Department of Interdisciplinary Medicine (DIM), University of Bari; Anesthesia, Intensive Care and Pain Unit, Policlinico Hospital, 70124 Bari, Italy

<sup>9</sup> Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy

**Collaborators:**

Abati Carlo, Abati Francesco, Abrardi Luca, Agricola Saverio Roberto, Aiello Angela, Albanese Valeria, Altavilla Lucia, Amedeo Pancotti, Angilletta Nadia, Balestra Roberta, Bambagioni Valentina, Baronio Manuela, Baruffi Francesca, Bastianetto Riccardo, Bellavia Giuseppe, Bersano Giovanni, Bertino Giuseppe, Bertolucci Andrea, Bigi Raffaella, Bilani Fisirela, Bondi Franca, Bonfante Paolo, Bonucci Alessandro, Bottino Francesca, Brogi Lorenzo, Brunetti Gregorio, Buffoli Laura, Busà Eros Matteo, Cagnazzo Maria, Calligaris Marta, Cancemi Chiara, Cantisani Egidia, Capuano Ida, Carnicella Aldo, Carrara Benigno, Catania Elvira, Cereda Stefano, Cervone Lucia, Chiara Pacifico, Chivu Lucian, Ciprian Nicoletta, Cocchiarella Antonio, Condello Tommaso, Corsi Giulio, Cossotto Donatella, Cuccu Giovanni, D'amato Giuseppe, De Lisi Alessandro, De Luca Michele, De Lucia Guido, De Ruvo Michele, De Tursi Michele, De Vita Caterina, Delli Santi Iris, Di Carlo Carmine, Di Maggio Giuseppe, Dongiovanni Diego, Fabiani Maria Grazia, Facilissimo Ivan, Falco Vincenzo, Faliva Alessio, Faraone Eugenio, Fares Maria Claudia, Fasano Morena, Favara Tommaso, Ferrari Gianmarco, Ferreri Andrea, Filippelli Gianfranco, Fiore Jessica, Fornaro Francesco, Franchi Benedetta, Galanti Daniele, Gallo Pasquale, Ginex Giuseppe, Giovinazzi Maria Giovanna, Glisci Saverio, Grande Roberta, Grassi Daniela, Grassi Maria Cristina, Guerrieri Giulia, La Sala Angela, Laudani Alessandro, Lo Mauro Mario, Loseto Valentina Concetta, Lugini Antonio, Lungu Vitalie, Mabilia Roberto, Macaluso Simona, Maccora Vito Emanuele, Maione Antonio, Mancuso Anna, Marchi Sabrina, Mareri Katia, Mariani Mario Martini Antonella, Massimino Luca, Matovic Mira, Mauceri Marco, Mauro Vassillo, Michele Carnovale, Minutillo Stefano, Modugno Donato, Moroni Emanuela, Napolitano Giuseppe, Nazzicone Giulia, Occhigrossi Felice, Orlandini Giulia, Orlando Francesco, Orsi Paola Maria, Pace Rosa, Pace Maurizio, Paladini Antonella, Palmieri Enzo, Passabì Emiliano, Pellegrini Alessandra, Pelliccione Michela, Pepe Vincenzo, Peretti Rossana, Perin

Roberta, Piccinelli Giovanni, Pignatelli Antonietta, Pinto Teodorico, Pirajno Giuseppe, Pollastrini Claudio, Polli Caterina, Pollina Vito, Pomillo Angelo, Portarena Ilaria, Potenza Ilenia, Provenzano Alessandra, Puglia Livio, Puglisi Teresa, Pusole Grazia, Raimondi Massimo, Rampello Elvira, Ravoni Giulio, Redivo Laura, Reglioni Simona, Ricchini Francesca, Ricciotti Maria Adelaide, Riolfi Mirko, Ronga Gianluca, Rossi Fabrizio, Russano Marco, Russo Paola, Satta Annalisa, Santoro Saverio, Savia Sebastiano, Sbalzer Nicola, Scibilia Carla, Semeraro Leonardo, Silveri Elisabetta, Spada Elisa, Spadaro Pietro, Tartaglia Laura, Tempera Settimio, Terranova Angela, Tibaldi Michela, Totaro Michele, Turchi Lorena, Vallisneri Cecilia, Zampi Maddalena, Zaza Angelo.

**Corresponding Author:**

Giustino Varrassi,

Paolo Procacci Foundation, Via Tacito 7, 00193 Rome, Italy

E-mail: giuvarr@gmail.com

## Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed drugs for cancer pain. We used Delphi methodology to evaluate the opinions of clinicians on NSAIDs and paracetamol, with a specific focus on their safety profile. Consensus was reached on 7 statements. High level of consensus was reached regarding use of NSAIDs and gastrointestinal, cardiovascular, and renal risk in patients taking low-dose aspirin and assessment of liver function during long-term treatment with paracetamol. Consensus was also reached that assessment and monitoring of eGFR is important in the elderly being administered NSAIDs. It was further agreed that NSAIDs can often play a key role in association with opioids in treatment of cancer pain and that paracetamol is the analgesic of first choice for patients with mild chronic pain. When NSAIDs are administered in combination with steroids, it was agreed that the risk of gastrointestinal damage is increased since steroids delay the healing of ulcers, and that paracetamol can be used during pregnancy and does not affect the health of the fetus. This Delphi study highlights that there is a poor agreement on how these drugs are routinely prescribed. However, the consensus was reached for 7 key statements and may represent a valid contribution to daily practice.

**Keywords:** Cancer pain, NSAIDs, paracetamol, adverse events

## Introduction

The vast majority of patients with cancer experience pain [1], and for many it is often poorly managed [2]. The WHO analgesic ladder provides recommendations for the treatment of cancer pain, including a three-step approach based on analgesics, with nonopioids, weak and strong opioids for mild, moderate, and severe pain, respectively [3]. In addition, oral administration of drugs should be favored whenever possible.

Current guidelines from the European Society for Medical Oncology (ESMO) highlight that paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) should be universally accepted [4]. However, high-quality evidence to support paracetamol alone or in combination with opioids is missing [5]. NSAIDs are among the most frequently prescribed drugs and are listed in the WHO's Essential Medicines. However, their adverse events include gastrointestinal, cardiovascular, hepatic, renal, cerebral, and pulmonary complications [6]. The type and dose of NSAID should be individualized after adequate stratification of the gastrointestinal and cardiovascular risk in each patient [7]. Clinicians often prescribe NSAIDs despite the lack of evidence in certain settings [8]. In some specific cases, a gastroprotective agent is co-prescribed, although this approach is not standardized. Proton-pump inhibitors significantly reduce the risk of gastrointestinal bleeding in high-risk patients, such as those using antiplatelet agents or oral anticoagulant drugs [9]. On the other hand, COX-2 selective agents, although safer for the gastrointestinal tract, have a worse cardiovascular profile, and should be theoretically avoided in patients with a high-risk of cardiovascular events and thrombosis, such as in cancer patients. However, the recent literature supports the hypothesis that COX-2 overexpression promotes tumor growth and that COX-2 inhibitors, as a combination strategy, may exert a therapeutic effect in cancer [10]. Furthermore, clinicians may have different perceptions of patients' pain and management [4].

The Rational Use of Analgesics (RUA) project is investigating the clinical management of cancer pain in Italy, which has found therapeutic challenges and prescription-related discrepancies between guidelines and routine clinical practice [11]. Furthermore, no consensus was found on the use of strong opioids [12]. Based on the Delphi methodology, we evaluated the opinions of attending physicians on NSAIDs and paracetamol, with a specific focus on their safety profile.

## Materials and methods

### *Study design*

A series of virtual meetings (the last one in March 2022) were conducted. A two-round Delphi approach was adopted [11]. A steering committee was selected, including experts in pain medicine, pharmacology, medical statistics, and palliative care: 7 persons met virtually to define a list of statements to be voted upon with a focus on the safety profile of NSAIDs and paracetamol. The statements dealt with aspects that the steering committee considered controversial, or for which limited information is available in the scientific literature.

### *Delphi process*

The Delphi process, which is an indirect, anonymous, iterative method aimed at achieving consensus among experts, is useful in situations where evidence is weak or missing [13,14]. Consensus can be achieved through a working group of experts using an interactive process of individual feedback. One hundred and sixty-three experts agreed to participate. The entire Delphi process was carried out virtually. In the first Delphi round, a brief overview of the project was provided. Each statement was presented, and voting was anonymously carried out. Using a 5-point Likert scale (0= totally disagree and 4= totally agree), consensus on a statement was achieved if the median consensus score (expressed as a value in which at least 50% of participants agreed) was at least 4 and the interquartile range (IQR) was 3-4. In the second Delphi round, statements for which consensus was not reached were revised by the steering committee based on feedback from the participants and voted upon during the successive Delphi session. According to national policies, Ethics Committee approval was not required.

### *Statistical analysis*

Qualitative variables were summarized with absolute and relative (percentage) frequencies, whereas quantitative variables were described with means (standard deviations) or medians (IQR) based on their parametric and non-parametric distribution, respectively. Chi-squared or Fisher exact tests were used to compare groups in relation to qualitative variables. A two-tailed p-value of less than 0.05 was considered statistically significant. The statistical software used for all statistical computations was STATA version 16 (StataCorp, Texas, US).



## Results

Panelists were representative of the entire national territory, and 141/163 participants were specialists: 29% were palliative care physicians, 24% were oncologists, and 19.5% worked in anesthesia, intensive care, and pain medicine. In addition, 39% had >20 years of experience in their field. Moreover, participants were mainly involved in home-based palliative care (56%) and outpatient clinics (32.7%).

Twenty-one statements were formulated by the steering committee and voted upon. Consensus was reached for 7/21 statements: 5 in the first and 2 in the second round (Table 1). Regarding use of NSAIDs in patients taking low-dose aspirin, consensus was not reached on the initial statement that almost all NSAIDs are contraindicated because they can increase the risk of gastrointestinal, cardiovascular, and renal events. However, high level of consensus was reached when the statement was changed to “NSAIDs increase gastrointestinal, cardiovascular, and renal risk in patients taking low-dose aspirin”. It was also agreed that liver function must be monitored during long-term treatment with paracetamol, and that assessment and monitoring of eGFR is important in the elderly when NSAIDs are prescribed. Moreover, it was confirmed the statement “NSAIDs can often play a key role in association with opioids in treatment of cancer pain”. Participants reached consensus that paracetamol is the analgesic of first choice for patients with mild chronic pain. When NSAIDs are administered in combination with steroids, it the statement that the risk of gastrointestinal damage is increased since steroids delay the healing of ulcers (micro-ulcers) was approved. Lastly, consensus was reached on the statement “paracetamol can be used during pregnancy and does not affect the health of the unborn child”.

In contrast, consensus was not reached for the remaining 14 statements which covered a broad range of topics, such as pharmacological properties of NSAIDs, fixed-dose

combinations, combination with anticoagulants, long-term administration, and safety (Table 2).

## Discussion and conclusion

The present work is an extension of a previous one, which achieved consensus on strong opioids and individualization of therapy in routine practice [12]. Herein, the overall aim was to achieve consensus on NSAID or non-opioid analgesic in patients with mild pain. Consensus was achieved for only 7 of the 21 statements. This highlights that there is a poor agreement on how these drugs are routinely prescribed.

In particular, disagreement was related to the role of NSAIDs in the increased risk of gastrointestinal, cardiovascular, and renal adverse events in patients taking low-dose aspirin. Several manuscripts have underscored this risk [15,16]. Risk of renal events may be associated with higher risk of incident eGFR  $<60$  ml/min per  $1.73\text{ m}^2$  and eGFR decline  $\geq 30\%$ , although the risk can vary according to the NSAID [17]. The recent recommendations of APAGE/APLAR/APSDE/APSH/APSN/PoA on patients with hypertension or cardiovascular, renal, or gastrointestinal comorbidities emphasize individual assessment before prescription [18]. In patients with high cardiovascular risk, naproxen and celecoxib are the preferred drugs. As a general rule, the lowest effective NSAID dose should be administered for the shortest period of time, while preferring an immediate release formulation [16]. In addition, concomitant use of a NSAID with corticosteroids, other antiplatelet/anticoagulation agents, or low-dose aspirin should be avoided [16].

There was broad consensus on monitoring of liver function during long-term exposure to paracetamol. Recently, several cases of paracetamol-induced liver intoxication have been described worldwide [19], and the highest dosages may lead to irreversible acute liver failure [20]. In reality, paracetamol overdose is the only recognized cause of hepatotoxicity, whereas

limited data are available regarding the potential toxicity of long-term use. Patients using paracetamol for chronic pain are 4-fold more likely to have slightly abnormal results on liver function tests and frail elderly patients may have reduced clearance of paracetamol glucuronide [21].

It was held that NSAIDs can play a key role in association with opioids in treatment of cancer pain. NSAIDs are widely used to treat cancer pain and are frequently used in combination with opioids [22]. NSAIDs are particularly useful as co-analgesics in the management of metastatic bone pain and in advanced cancers, although the risk of long-term adverse effects should be quantified even in the cancer setting. Non-opioid analgesics are recommended for this purpose in the WHO treatment ladder, either alone or in combination with opioids. Notwithstanding, limited evidence is available on the combined prescription of NSAIDs and opioids [23].

Assessment and monitoring of eGFR is recommended in the elderly to select the most appropriate analgesic, being NSAIDs associated with acute renal failure [24].

The PAGE/APLAR/APSDE/APSH/APSN/PoA includes the elderly in the category of 'high-risk' patients, and renal function should be monitored if not carried out in the past 6 months [18].

Paracetamol was also considered the first choice in mild chronic pain in agreement with the current literature [25]. In addition, a review of guideline recommendations found that the majority recommend paracetamol as first- or second-line for both acute and chronic pain [26]. It can be prescribed to patients with limited therapeutic options, for those with liver, kidney or cardiovascular diseases, and gastrointestinal disorders, as well as in the elderly [25,26]. Moreover, kidney disease has been shown to be highly prevalent in cancer patients. Therefore, evaluation of creatinine clearance should drive the correct analgesic prescription and dosage adaptation [27].

Consensus was also reached on the statement related to the increased gastrointestinal risk when steroids are prescribed with NSAIDs, since steroids delay the healing of ulcers (micro-ulcers), as previously demonstrated [28]. More recently, it was reported that short-term administration of steroids may be associated with gastrointestinal bleeding, which is increased by the concomitant administration of NSAIDs [29]. In an analysis of over 2,000 cases of upper gastrointestinal complications, steroids were associated with an increased risk of bleeding (OR 1.8) and concurrent use of steroids with low-medium and high doses of a NSAID was associated with ORs of 4.0 and 12.7, respectively [30].

The last statement achieving consensus was on use of paracetamol during pregnancy and the safety of the unborn child. Historically, paracetamol has been considered safe for use in pregnancy [31,32]. However, caution on paracetamol during pregnancy has recently been advocated since it may increase the risk of neurodevelopmental, reproductive, and urogenital disorders [31]. It may also be associated with sleep and attention problems in children [33]. Given these concerns, the lowest effective dose for the shortest possible time should be administered [31].

The statements not reaching consensus covered several topics, including pharmacological interactions, mechanism of action and pharmacological properties, combination with oral anticoagulants, and choice of NSAID: this seems to underscore poor heterogeneity in routine practice. Clear recommendations, based on high-quality evidence, and improved education on NSAIDs are thus needed. This missing consensus can indeed be considered a study limitation. However, the consensus reached for 7 key statements may represent a valid contribution to daily practice.

**Funding**

Unrestricted editorial support was funded by L. Molteni & C Dei Fratelli Alitti. L. Molteni & C Dei Fratelli Alitti had no role in the design, execution, interpretation, or writing of the study.

**Acknowledgments**

The publishing process has been possible thanks to the unconditional support of the Paolo Procacci Foundation. Editorial support was provided by Content Ed Net, with the helpful contribution of Patrick Moore, PhD, Medical Writer, in drafting the manuscript.

**Author Contributions**

All authors contributed to conceptualization, writing and review of the manuscript. All authors read and approved the manuscript version submitted.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of interest**

GV is President of the Paolo Procacci Foundation. He is also consultant for several pharmaceutical companies and serves in some Editorial Board of scientific journals. DF declares relationships during the past 2 years as conference speaker, member of advisory boards or consultant for the following pharmaceutical companies: Abiogen, Alfasigma, Angelini, Bayer, Grunenthal, Lundbeck, Molteni, SPA. The authors report no other conflicts of interest in this work.

## References

1. Breivik, H.; Cherny, N.; Collett, B.; de Conno, F.; Filbet, M.; Foubert, A.J.; Cohen, R.; Dow, L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. *Ann Oncol* **2009**, *20*, 1420-1433, doi:10.1093/annonc/mdp001.
2. Deandrea, S.; Montanari, M.; Moja, L.; Apolone, G. Prevalence of undertreatment in cancer pain. A review of published literature. *Ann Oncol* **2008**, *19*, 1985-1991, doi:10.1093/annonc/mdn419.
3. WHO: World Health Organization Cancer Pain Relief, With a Guide to Opioid Availability (ed 2). Geneva, Switzerland, World Health Organization, 1996.
4. Fallon, M.; Giusti, R.; Aielli, F.; Hoskin, P.; Rolke, R.; Sharma, M.; Ripamonti, C.I.; Committee, E.G. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. *Ann Oncol* **2018**, *29*, iv166-iv191, doi:10.1093/annonc/mdy152.
5. Wiffen, P.J.; Derry, S.; Moore, R.A.; McNicol, E.D.; Bell, R.F.; Carr, D.B.; McIntyre, M.; Wee, B. Oral paracetamol (acetaminophen) for cancer pain. *Cochrane Database Syst Rev* **2017**, *7*, CD012637, doi:10.1002/14651858.CD012637.pub2.
6. Bindu, S.; Mazumder, S.; Bandyopadhyay, U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. *Biochem Pharmacol* **2020**, *180*, 114147, doi:10.1016/j.bcp.2020.114147.
7. Domper Arnal, M.J.; Hijos-Mallada, G.; Lanas, A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. *Expert Opin Drug Saf* **2022**, *21*, 373-384, doi:10.1080/14740338.2021.1965988.
8. Strawson, J. Nonsteroidal anti-inflammatory drugs and cancer pain. *Curr Opin Support Palliat Care* **2018**, *12*, 102-107, doi:10.1097/SPC.0000000000000332.
9. Ahn, H.J.; Lee, S.R.; Choi, E.K.; Rhee, T.M.; Kwon, S.; Oh, S.; Lip, G.Y.H. Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients

- receiving oral anticoagulants: A systematic review and meta-analysis. *Br J Clin Pharmacol* **2022**, 88, 4676-4687, doi:10.1111/bcp.15478.
10. Pu, D.; Yin, L.; Huang, L.; Qin, C.; Zhou, Y.; Wu, Q.; Li, Y.; Zhou, Q.; Li, L. Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer. *Front Oncol* **2021**, 11, 637504, doi:10.3389/fonc.2021.637504.
  11. Varrassi, G.; De Conno, F.; Orsi, L.; Puntillo, F.; Sotgiu, G.; Zeppetella, J.; Zucco, F. Cancer Pain Management: An Italian Delphi Survey from the Rational Use of Analgesics (RUA) Group. *J Pain Res* **2020**, 13, 979-986, doi:10.2147/JPR.S243222.
  12. Varrassi, G.; Coluzzi, F.; Guardamagna, V.A.; Puntillo, F.; Sotgiu, G.; Vellucci, R.; Rational Use of Analgesics, G. Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group. *Pain Ther* **2021**, 10, 605-617, doi:10.1007/s40122-021-00248-x.
  13. Humphrey-Murto, S.; Varpio, L.; Gonsalves, C.; Wood, T.J. Using consensus group methods such as Delphi and Nominal Group in medical education research(). *Med Teach* **2017**, 39, 14-19, doi:10.1080/0142159X.2017.1245856.
  14. Jones, J.; Hunter, D. Consensus methods for medical and health services research. *BMJ* **1995**, 311, 376-380, doi:10.1136/bmj.311.7001.376.
  15. Baker, M.; Perazella, M.A. NSAIDs in CKD: Are They Safe? *Am J Kidney Dis* **2020**, 76, 546-557, doi:10.1053/j.ajkd.2020.03.023.
  16. Brune, K.; Patrignani, P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. *J Pain Res* **2015**, 8, 105-118, doi:10.2147/JPR.S75160.
  17. Wan, E.Y.F.; Yu, E.Y.T.; Chan, L.; Mok, A.H.Y.; Wang, Y.; Chan, E.W.Y.; Wong, I.C.K.; Lam, C.L.K. Comparative Risks of Nonsteroidal Anti-Inflammatory Drugs on CKD. *Clin J Am Soc Nephrol* **2021**, 16, 898-907, doi:10.2215/CJN.18501120.

18. Szeto, C.C.; Sugano, K.; Wang, J.G.; Fujimoto, K.; Whittle, S.; Modi, G.K.; Chen, C.H.; Park, J.B.; Tam, L.S.; Vareesangthip, K.; et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. *Gut* **2020**, *69*, 617-629, doi:10.1136/gutjnl-2019-319300.
19. Jozwiak-Bebenista, M.; Nowak, J.Z. Paracetamol: mechanism of action, applications and safety concern. *Acta Pol Pharm* **2014**, *71*, 11-23.
20. O'Neil, C.K.; Hanlon, J.T.; Marcum, Z.A. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. *Am J Geriatr Pharmacother* **2012**, *10*, 331-342, doi:10.1016/j.amjopharm.2012.09.004.
21. Conaghan, P.G.; Arden, N.; Avouac, B.; Migliore, A.; Rizzoli, R. Safety of Paracetamol in Osteoarthritis: What Does the Literature Say? *Drugs Aging* **2019**, *36*, 7-14, doi:10.1007/s40266-019-00658-9.
22. McNicol, E.D.; Strassels, S.; Goudas, L.; Lau, J.; Carr, D.B. WITHDRAWN: NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. *Cochrane Database Syst Rev* **2015**, CD005180, doi:10.1002/14651858.CD005180.pub2.
23. Derry, S.; Wiffen, P.J.; Moore, R.A.; McNicol, E.D.; Bell, R.F.; Carr, D.B.; McIntyre, M.; Wee, B. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. *Cochrane Database Syst Rev* **2017**, *7*, CD012638, doi:10.1002/14651858.CD012638.pub2.
24. Griffin, M.R.; Yared, A.; Ray, W.A. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. *Am J Epidemiol* **2000**, *151*, 488-496, doi:10.1093/oxfordjournals.aje.a010234.



25. Alchin, J.; Dhar, A.; Siddiqui, K.; Christo, P.J. Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older. *Curr Med Res Opin* **2022**, *38*, 811-825, doi:10.1080/03007995.2022.2049551.
26. Freo, U.; Ruocco, C.; Valerio, A.; Scagnol, I.; Nisoli, E. Paracetamol: A Review of Guideline Recommendations. *J Clin Med* **2021**, *10*, doi:10.3390/jcm10153420.
27. Coluzzi, F. Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease. *Drugs* **2018**, *78*, 1459-1479, doi:10.1007/s40265-018-0980-9.
28. Carpani de Kaski, M.; Rentsch, R.; Levi, S.; Hodgson, H.J. Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. *Gut* **1995**, *37*, 613-616, doi:10.1136/gut.37.5.613.
29. Tseng, C.L.; Chen, Y.T.; Huang, C.J.; Luo, J.C.; Peng, Y.L.; Huang, D.F.; Hou, M.C.; Lin, H.C.; Lee, F.Y. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. *Aliment Pharmacol Ther* **2015**, *42*, 599-606, doi:10.1111/apt.13298.
30. Hernandez-Diaz, S.; Rodriguez, L.A. Steroids and risk of upper gastrointestinal complications. *Am J Epidemiol* **2001**, *153*, 1089-1093, doi:10.1093/aje/153.11.1089.
31. Bauer, A.Z.; Swan, S.H.; Kriebel, D.; Liew, Z.; Taylor, H.S.; Bornehag, C.G.; Andrade, A.M.; Olsen, J.; Jensen, R.H.; Mitchell, R.T.; et al. Paracetamol use during pregnancy - a call for precautionary action. *Nat Rev Endocrinol* **2021**, *17*, 757-766, doi:10.1038/s41574-021-00553-7.
32. Coluzzi, F.; Valensise, H.; Sacco, M.; Allegri, M. Chronic pain management in pregnancy and lactation. *Minerva Anesthesiol* **2014**, *80*, 211-224.

33. Sznajder, K.K.; Teti, D.M.; Kjerulff, K.H. Maternal use of acetaminophen during pregnancy and neurobehavioral problems in offspring at 3 years: A prospective cohort study. *PLoS One* **2022**, *17*, e0272593, doi:10.1371/journal.pone.0272593.

Table 1. Statements for which consensus was reached.

| STATEMENT   | REVISED STATEMENT   | SCORE GIVEN<br>N (%) |          |               |               |               | MEDIA<br>N<br>(IQR) |
|---|---|----------------------|----------|---------------|---------------|---------------|---------------------|
|   |   | 0                    | 1        | 2             | 3             | 4             |                     |
| In patients taking low-dose aspirin almost all NSAIDs are contraindicated because they increase the risk of gastrointestinal, cardiovascular and renal events | NSAIDs increase gastrointestinal, cardiovascular and renal risk in patients taking low-dose aspirin | 1<br>(0.78)          | 6 (4.69) | 11 (8.59)     | 37<br>(28.91) | 73<br>(57.03) | 4 (3-4)             |
| Liver function should be monitored during long-term treatment with paracetamol  |   | 0<br>(0.00)          | 0 (0.00) | 5 (3.91)      | 34<br>(26.56) | 89<br>(69.53) | 4 (3-4)             |
| NSAIDs can often play a key role in association with opioids in treatment of cancer pain  |   | 1<br>(0.78)          | 4 (3.13) | 11 (8.59)     | 34<br>(26.56) | 78<br>(60.94) | 4 (3-4)             |
| Assessment and monitoring of eGFR is recommended in the elderly to select the most appropriate analgesic  | Assessment and monitoring of eGFR is important in the elderly when using NSAIDs                     | 1<br>(0.78)          | 3 (2.34) | 19<br>(14.84) | 33<br>(25.78) | 72<br>(56.25) | 4 (3-4)             |
| Paracetamol is the analgesic of first choice in mild chronic pain   |   | 4<br>(3.13)          | 5 (3.91) | 12 (9.38)     | 28<br>(21.88) | 79<br>(61.72) | 4 (3-4)             |
| The association of steroids with NSAIDs increases the gastrointestinal damage caused by the latter since steroids delay the healing of ulcers (micro-ulcers)  |   | 1<br>(0.78)          | 8 (6.25) | 11 (8.59)     | 40<br>(31.25) | 68<br>(53.13) | 4 (3-4)             |
| Paracetamol can be used during pregnancy and does not affect the health of the unborn child   |   | 0<br>(0.00)          | 4 (3.13) | 12 (9.38)     | 43<br>(33.59) | 69<br>(53.91) | 4 (3-4)             |

Table 2. Statements for which consensus was not reached.

| STATEMENT  | REVISED STATEMENT  | 0          | 1          | 2          | 3          | 4          | MEDIAN (IQR) |
|--|--|------------|------------|------------|------------|------------|--------------|
| Paracetamol has no anti-inflammatory properties; its analgesic properties are not dependent on COX inhibition                                |  | 8 (6.25)   | 11 (8.59)  | 13 (10.16) | 29 (22.66) | 67 (52.34) | 4 (2.5-4)    |
| All NSAIDs, selective, preferential, and traditional, especially at high doses, increase cardiovascular risk by inhibiting endothelial COX-2 | Traditional NSAIDs and not just COX inhibitors inhibit endothelial COX2 and increase cardiovascular risk, especially at high doses | 2 (1.56)   | 8 (6.25)   | 16 (12.50) | 51 (39.84) | 51 (39.84) | 3 (3-4)      |
| NSAIDs, like many other drugs, can cause a variety of adverse reactions due to individual genetic variance                                   |  | 2 (1.56)   | 8 (6.25)   | 19 (14.84) | 45 (35.16) | 54 (42.19) | 3 (3-4)      |
| NSAIDs, by inhibiting COX in inflamed tissues, counteract peripheral sensitization   |  | 4 (3.13)   | 6 (4.69)   | 20 (15.63) | 44 (34.38) | 54 (42.19) | 3 (3-4)      |
| It is always possible to prescribe acetaminophen in combination with oral anticoagulants   |  | 6 (4.69)   | 13 (10.16) | 18 (14.06) | 42 (32.81) | 49 (38.28) | 3 (2-4)      |
| Fixed-dose combinations of paracetamol and other drugs are indicated in the treatment of acute pain or exacerbations of chronic pain         | Fixed-dose combinations of paracetamol and opioids are indicated in treatment of acute pain or exacerbations of chronic pain       | 17 (13.28) | 15 (11.72) | 13 (10.16) | 43 (33.59) | 40 (31.25) | 3 (1.5-4)    |
| Metamizole has analgesic, antipyretic, and antispasmodic properties but not anti-inflammatory  | Metamizole is an analgesic, antipyretic, and antispasmodic drug, with unclear anti-inflammatory properties                         | 12 (9.38)  | 12 (9.38)  | 27 (21.09) | 41 (32.03) | 36 (28.13) | 3 (2-4)      |

|  |  |               |               |               |               |               |         |
|--|--|---------------|---------------|---------------|---------------|---------------|---------|
| In patients with renal insufficiency, the use of paracetamol does not require dose adjustments   | The daily dose of paracetamol does not need to be adjusted in patients with renal insufficiency                  | 22<br>(17.19) | 23<br>(17.97) | 17<br>(13.28) | 35<br>(27.34) | 31<br>(24.22) | 3 (1-3) |
| NSAIDs are not appropriate for the long-term treatment of chronic inflammatory pain, as they mainly act on peripheral inflammatory processes                                   | NSAIDs act as peripheral anti-inflammatories and are not indicated for chronic pain                              | 18<br>(14.06) | 15<br>(11.72) | 26<br>(20.31) | 34<br>(26.56) | 35<br>(27.34) | 3 (1-4) |
| In the choice of NSAIDs, ibuprofen, diclofenac or ketorolac should be preferred to piroxicam, indomethacin or naproxen in patients at risk of gastrointestinal adverse events. | Ibuprofen and diclofenac have lower gastrointestinal toxicity than piroxicam and indomethacin                    | 15<br>(11.72) | 16<br>(12.50) | 15<br>(11.72) | 43<br>(33.59) | 39<br>(30.47) | 3 (2-4) |
| Gastrointestinal toxicity from NSAIDs can be mitigated by intervening on intestinal microbiota   | Intestinal microbiota can improve intestinal homeostasis by reducing the risk of NSAID-related enteropathy       | 10<br>(7.81)  | 7 (5.47)      | 22<br>(17.19) | 43<br>(33.59) | 46<br>(35.94) | 3 (2-4) |
| Steroids do not cause extensive gastrointestinal damage, and at least in the short to medium term gastroprotection is not required   | During steroid therapy, gastric protection is needed only for long-term treatment and not for short-term therapy | 26<br>(20.31) | 15<br>(11.72) | 6 (4.69)      | 38<br>(29.69) | 43<br>(33.59) | 3 (1-4) |
| All SSRIs interact with NSAIDs, increasing their gastrointestinal risk   | The gastrointestinal risk from NSAIDs is greater in patients taking SSRIs  | 16<br>(12.50) | 21<br>(16.41) | 29<br>(22.66) | 32<br>(25.00) | 30<br>(23.44) | 2 (1-3) |
| Chronic use of paracetamol in patients taking salicylates is not recommended due to the risk of nephropathy  | In patients taking salicylates, chronic use of high-dose paracetamol increases the risk of nephropathy           | 22<br>(17.19) | 25<br>(19.53) | 24<br>(18.75) | 31<br>(24.22) | 26<br>(20.31) | 2 (1-3) |

